OOIR: Observatory of International Research

Papers

(The H4-Index of Inflammatory Bowel Diseases is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
ARTHRITIS AND ARTHRALGIA AS EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB: A META-ANALYSIS	142
THE ONSET AND SEVERITY OF ULCERATIVE COLITIS IN IL-10 -/- MICE IS NOT DEPENDENT ON FECAL MICROBIOTA TRANSPLANTATION FROM ULCERATIVE COLITIS PATIENTS	69
NOVEL FUNCTION OF MYELOID METHYLTRANSFERASE SMYD5 IN INFLAMMATORY BOWEL DISEASE PROGRESSION	67
EFFECTS OF DELAYED ENDOSCOPIES IN INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC	65
INCREASE IN MK2 ACTIVITY IN CROHN’S DISEASE: ROLE IN THE INFLAMMATORY ACTIVATION OF FIBROBLASTS	53
Is it a Flare? Acute Appendicitis in Ulcerative Colitis Patient Found on Routine Screening Colonoscopy	49
Preoperative Use of Multiple Advanced Therapies Is Not Associated With Endoscopic Inflammatory Pouch Diseases	49
Squamous Cell Carcinoma of the Pouch	48
Secondary Indicators for an Evaluation and Guidance System for Quality of Care in Inflammatory Bowel Disease Centers: A Critical Review of the Inflammatory Bowel Disease Quality of Care Center	47
Unilateral Painless Vulval Swelling Presenting as an Adverse Reaction to Adalimumab	47
LONG TERM ADVERSE HEALTH OUTCOMES IN OFFSPRING FROM MOTHERS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE POPULATION BASED STUDY IN KOREA	46
Correction to: Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease	45
MATRIX METALLOPROTEINASE (MMP-9) INDUCED INCREASE IN INTESTINAL EPITHELIAL TIGHT JUNCTION BARRIER IS MEDIATED BY EGFR ACTIVATION	44
THE CROHN’S AND COLITIS DISTRESS SCALE: ASSESSING THE DOMAINS OF IMPACT IN YOUTH WITH IBD	43
GRANZYME A-PRODUCING CD4 T CELLS ARE DRIVERS OF IMMUNE CHECKPOINT BLOCKADE-INDUCED COLITIS	41
DEPRESSION MAY BE A STRONGER UNIQUE PREDICTOR OF FATIGUE THAN SELF-REPORTED IBD DISEASE ACTIVITY	41
LOWER MORTALITY RISK WITH COMBINATION THERAPY WITH ANTI-TNF THERAPY AND THRIOPURINE COMPARED TO THIOPURINE ALONE IN ELDERLY PATIENTS WITH UC	41
EPITHELIAL MITOCHONDRIAL DYSFUNCTION IN CHRONIC POUCHITIS	39
GROUP 3 INNATE LYMPHOID CELLS RELY ON ER STRESS RESPONSE FOR CYTOKINE PRODUCTION IN IBD	39
COMPARATIVE EFFECTIVENESS OF ORAL JANUS KINASE INHIBITORS VERSUS VEDOLIZUMAB IN ULCERATIVE COLITIS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS	38
Gut Feelings Matter: The Unresolved Questions of Irritable Bowel Syndrome-Like Symptoms in Inflammatory Bowel Disease in Remission	38
COMPARATIVE EFFICACY OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UC PATIENTS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS	38
DELAYS IN THE ADMINISTRATION OF BIOLOGIC THERAPIES AND ADVERSE OUTCOMES IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY	38
Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN	37
Pharmacogenomic Assessment of Genes Implicated in Thiopurine Metabolism and Toxicity in a UK Cohort of Pediatric Patients With Inflammatory Bowel Disease	36

A Case of Ulcerative Colitis Relapse Characterized by Systemic Type I Interferon Responses after COVID-19 Vaccination	35
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis	34
Improving Brain–Gut Studies in Crohn’s Disease: Methodological Considerations	34
IDENTIFYING THE ROLE OF ACINETOBACTER CALCOACETICUS IN DRIVING INTESTINAL INFLAMMATION	34
Phosphoproteomics Reveals Novel Insights into the Pathogenesis and Identifies New Therapeutic Kinase Targets of Ulcerative Colitis	33
Vitamin D3 andLactobacillus rhamnosusGG/p40 Synergize to Protect Mice From Colitis by Promoting Vitamin D Receptor Expression and Epithelial Proliferation	33
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OL	32
Multisegmental Hypoganglionosis: A Rare Cause of Recurrent Bowel Obstruction and Intestinal Ulcers	32
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED	32
Impact of Psychosocial and Neurodevelopmental Disorders on Pediatric Ulcerative Colitis: A Single-Center, Retrospective, Observational Study	32